The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Footsie finishes flat after long weekend

Tue, 28th Aug 2012 16:48

- Markets await Jackson Hole symposium- Miners lower on concerns over Japan- Chemring drops after profit warning. Concerns about global economic growth were weighing on sentiment on Tuesday, meaning that the FTSE 100 was little changed by the close despite some volatile swings between gains and losses throughout the session.Meanwhile, speculation about quantitative easing (QE) measures from the US Federal Reserve was continuing to do the rounds. Market strategist Brenda Kelly from CMC Markets said: "The almost absolute certainty displayed in recent price action that the Fed would ease at Jackson Hole this weekend seems to have petered out, with the major European indices pulling back further from their recent highs and entering a consolidative mode." The Japanese government reduced its assessment of the economy today, warning that a slowdown in economic growth overseas and the ongoing Eurozone debt crisis are key risks to the world's third-largest economy. JPMorgan Securities Japan and BNP Paribas are forecasting a 0.3% and 0.9% decline in third-quarter Japanese gross domestic product (GDP), respectively. Japan's concerns about economic growth overseas will likely have been exacerbated after the release of some gloomy figures from China and Spain. It was a revealed yesterday that combined profits in the industrial sector in China, a major trade partner to Japan, dropped by a year-on-year rate of 5.4% in July, worse than the 1.7% decline seen the month before.Meanwhile, Spanish GDP declined at a 1.3% annual rate in the second quarter, compared with the initial estimate of a 1% contraction, the country's national statistics office said. News that the Generalitat of Catalonia will request €5.023bn from the Spanish government's liquidity fund spooked markets today, dampening earlier optimism after a successful short-term bond auction which saw borrowing costs drop and demand improve.FTSE 100: Miners drop on Japanese concerns; G4S falls after first-half results Miners were firmly out of favour today on concerns over the Japanese economy. BHP Billiton fell after announcing the sale of its Yeelirrie uranium deposit in Western Australia to Cameco for $430m. BHP and sector peers ENRC, Kazakhmys and Vedanta were also lower after Morgan Stanley reduced its target price for all four stocks. Security giant G4S fell after expressing disappointment over the problems related to its Olympics contract, saying that it will incur a £50m loss on the contract in the first half. Meanwhile, the company said that a review of its overhead structure will lead the loss of 1,100 jobs. Nevertheless, the firm revealed that turnover at constant exchange rates rose 7.5% while profits were flat. Retail peers M&S and Kingfisher were both lower this afternoon. M&S was pulling back after a sharp rise on Friday after rumours that private equity titan CVC Capital Partners is considering a takeover offer. Meanwhile, B&Q owner Kingfisher was lower after Bank of America Merrill Lynch lowered its rating to 'underperform'. Drugs giant AstraZeneca was lower after saying that it has appointed Roche's Chief Operating Officer as its new Chief Executive Officer. Meanwhile, the firm also announced that the European Commission has granted marketing authorisation to its ZINFORO treatment. Sector peer GlaxoSmithKline was suffering from a downgrade by UBS. Bunzl, the international distribution and outsourcing group, fell despite saying that pre-tax profits and revenues in the first half rose 9% and 7%, respectively. Telecoms group BT rose after Credit Suisse reiterated its 'outperform' rating and saying that it expects BT, along with BSkyB to take broadband market share.FTSE 250: Chemring drops after profit warning Defence contractor Chemring dropped after it issued a profits warning, saying a computer glitch and production delays are likely to wipe £15m off full-year earnings as it considers a takeover offer from private equity giant Carlyle. Heading the other way was chemicals group Yule Catto after reporting a pre-tax profit of £56m in the first half, up from £52.4m the year before. Sales, however, fell to £603.3m from £664.3m. FTSE 100 - RisersGlencore International (GLEN) 384.00p +4.67%Carnival (CCL) 2,170.00p +3.73%International Consolidated Airlines Group SA (CDI) (IAG) 144.90p +2.48%BT Group (BT.A) 219.50p +2.00%Capital Shopping Centres Group (CSCG) 334.60p +1.73%Xstrata (XTA) 939.20p +1.24%ITV (ITV) 84.40p +1.02%Barclays (BARC) 188.95p +0.93%Ashmore Group (ASHM) 334.20p +0.81%CRH (CRH) 1,140.00p +0.80%FTSE 100 - FallersEurasian Natural Resources Corp. (ENRC) 318.60p -5.99%Evraz (EVR) 233.90p -5.23%Kazakhmys (KAZ) 634.00p -4.01%Kingfisher (KGF) 276.00p -3.40%Marks & Spencer Group (MKS) 362.80p -2.39%Vedanta Resources (VED) 904.00p -2.22%G4S (GFS) 261.00p -1.95%Rio Tinto (RIO) 2,862.00p -1.65%Intertek Group (ITRK) 2,715.00p -1.52%IMI (IMI) 844.50p -1.46%FTSE 250 - RisersYule Catto & Co (YULC) 158.00p +11.42%Moneysupermarket.com Group (MONY) 139.20p +6.26%Ted Baker (TED) 1,017.00p +5.17%Imagination Technologies Group (IMG) 595.00p +5.03%Centamin (DI) (CEY) 79.10p +3.87%Renishaw (RSW) 1,573.00p +2.88%Menzies(John) (MNZS) 620.00p +2.73%Carpetright (CPR) 640.00p +2.32%Dialight (DIA) 1,097.00p +2.14%Britvic (BVIC) 315.00p +1.65%FTSE 250 - FallersChemring Group (CHG) 324.00p -12.55%BTG (BTG) 300.30p -5.77%Cairn Energy (CNE) 283.70p -4.25%Bumi (BUMI) 340.00p -4.23%Afren (AFR) 124.70p -4.00%EnQuest (ENQ) 111.90p -2.86%Ophir Energy (OPHR) 531.00p -2.84%Man Group (EMG) 73.60p -2.84%Cape (CIU) 187.70p -2.80%Hunting (HTG) 771.50p -2.77%BC
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.